PMC9557219_01
CT scans showing changes in the three lesions during the whole treatment. (A1-7) show the dynamic changes of the L1. (B1-7) show the dynamic changes of the L2. (C1-7) show the dynamic changes of the L3.
fonc-12-977065-g001.jpg
PMC9557219_01_fonc-12-977065-g001.jpg
f1
Her chest enhanced CT showed one subsolid node in each of the left upper lobe, right middle lobe, and right lower lobe ( Figures 1A1, B1, C1 ). The patient started oral icotinib 125 mg Q8H treatment on June 15, 2018, and the three cancer lesions all showed persistent good responses ( Figures 1A1-4, B1-4, C1-4 ) until September 22, 2021, when re-examination by chest CT showed that all three lesions had grown and progressed ( Figures 1A5, B5, C5 ). The efficacy in the right lower lobe lesion (L3) was evaluated as progressive disease ( Figures 1C5-6 ).
Location, pathology, and ongoing NGS-testing results of the three pulmonary lesions. NGS, next-generation sequencing.
fonc-12-977065-g002.jpg
PMC9557219_01_fonc-12-977065-g002.jpg
f2
The efficacy in the right lower lobe lesion (L3) was evaluated as progressive disease ( Figures 1C5-6 ). The location, pathology, and ongoing NGS-testing results of the three pulmonary lesions were showed in  Figure 2 .
Mechanisms of drug resistance associated with using first generation EGRFR-TKI as first-line treatment for lung adenocarcinoma with EGFR mutation. EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
fonc-12-977065-g003.jpg
PMC9557219_01_fonc-12-977065-g003.jpg
f3
The efficacy in the right lower lobe lesion (L3) was evaluated as progressive disease ( Figures 1C5-6 ).